Has WHO’s IARC cancer agency, partly funded by US, outlived its usefulness?

Screen Shot at PM

The International Agency for Research on Cancer (IARC) has recently hit new lows in disgraceful behavior. Over the last 18 months, the Risk-Monger and others have been cataloging examples of a lack of scientific integrity, but recent revelations of inappropriate and unethical activities by IARC staff have brought the WHO agency down to its knees. This blog will show the following:

  • IARC’s Kate Guyton tried to suppress glyphosate panel members from cooperating with freedom of information requests;
  • IARC’s director, Christopher Wild, interfered with a US Congressional committee’s internal investigation;
  • IARC panel members were found to be meddling with US EPA research on glyphosate;
  • IARC’s communication team displayed a series of unethical dirty tricks;
  • A study has just been published where ten toxicologists show how IARC’s hazard assessment is outmoded and inadequate.

These events have taken place in the last two weeks and clearly, indicates that IARC is not fit for purpose. Before getting into the details, here is a bit of history of how far IARC has fallen from respectability and scientific credibility.

Some sorry stories of a fall from grace

In March 2015, the IARC Monograph 112 working group met to discuss certain pesticides including glyphosate, which, against the widespread scientific view, they declared to be carcinogenic. It was soon revealed that:

  • IARC had cherry-picked the studies to include in their evaluation;
  • The studies were of a very low quality (mostly not fit for peer review);
  • Monograph lead author, Guyton, had announced at an anti-chemical NGO meeting the year before that they would find certain pesticides carcinogenic;
  • Environmental Defense Fund activist, Christopher Portier, chaired IARC’s independent advisory group that recommended doing a monograph on glyphosate;
  • Portier sat as the only external technical advisor to the glyphosate working group;
  • IARC did not declare Portier’s affiliations with EDF, even though they knew about this clear conflict of interest at least six months earlier;
  • IARC did not distance itself from Portier’s political lobbying using his affiliation with the working group;
  • Rather, IARC went on the offensive, attacking scientists and agencies who disagreed with their findings, including EFSA and the German BfR;
  • IARC’s communications team went so far as to provide information to an activist writer in Le Monde to attack EFSA;
  • IARC diminished industry studies and rejected any involvement, advice or data of industry experts.
  • Their anti-industry bias is outrageous. At IARC’s 50th anniversary, which had over 1000 cancer researchers and administrators in attendance, not a single industry cancer researcher from the pharmaceutical industry was invited.

The sources, research, and analyses of these claims can be found in the blogs assembled in my Glyphosate Issue page. This has become known as IARCgate.

But it has recently got far worse, and IARC seems to be impervious to the crises erupting all around them. Here is a scan of scandals that would force any reputable agency to take immediate action to rectify!

Unethical and Uncooperative

Reuters reported on 25 October 2016 how in April 2016 (just as IARCgate was erupting), Kate Guyton instructed IARC glyphosate panel members to not cooperate with FOIAs (today’s equivalent to “shred all documents”). They were instructed to withhold all documents related to panel discussions.

The day after, IARC issued a press release which attacked Reuters for being misleading. But their story was not credible. They declared that they were merely giving advice to scientists who felt they were being threatened by Monsanto (the law firm making the FOIA request was E&E Legal which IARC suggests represents Monsanto). One problem though is that the FOIA was made in May, well after IARC’s April message to the scientists. Another little problem, as the correction in the comments section to this blog attest, the firm E&E Legal does not represent Monsanto. Conclusion: unless they can provide further evidence, this IARC press release is entirely a fiction!

Trying to show Reuters bought by Monsanto? A bit unethical perhaps!
Trying to show Reuters bought by Monsanto? A bit unethical perhaps!

To make matters worse, the IARC press release led with a screenshot of the Reuters web page (not a professional procedure for press releases!). The screenshot was not just the Reuters article, but also an ad in the side column from Bayer offering information on their takeover of Monsanto. The image on the ad was of the two CEOs shaking hands. By putting the picture of the Monsanto CEO next to the article, IARC was trying to push the impression of Monsanto having an influence on Reuters. And IARC accused Reuters of being misleading!

The IARC communications team used a network of activists to push their press release. The US Right to Know activist campaigner and glyphosate fear-monger, Carey Gillam, tweeted the news of the IARC response to Reuters well before it was published on the IARC website. I caught the IARC communications team acting unethically in April of this year when they used a Le Monde activist writer to attack EFSA, so this deplorable abuse of the activist media is nothing new. See the research from the Clear Food twitter page:

At 12:15 central time, Gillam posts her tweet with IARC's response
Gillam posts her tweet with IARC’s response at 10:19 AM
screen-shot-2016-11-02-at-8-41-27-am
(left) Hours after the Gillam tweet, IARC has not updated site to include its response. (right) IARC publishes its response almost 6 hours after Carey Gillam tweeted it (credit: @clear_food)

This indicates a complete lack of moral leadership in IARC, and I can only imagine that its director, Christopher Wild, to preserve the respect of the agency, will need to step down.

Colluding and Colliding

NIH veteran, Professor Bruce Chassy published a piece in The Hill on 24 October 2016 showing an exceptionally high level of NGO activist engagement from IARC panel members. He suggested this could explain why the NIH requested that the House hearing not be public. Activist infiltration, as well as a clear anti-industry bias, seems to be choking the credibility of the agency.

IARC director, Christopher Wild, wrote a letter to the US NIH head, Francis Collins, when the US House Chairman of the Committee on Oversight and Government Reform, Jason Chaffetz, requested a meeting with the head of the NIH to consider whether the US should continue to fund IARC. Wild’s collusion into the internal government decision-making process is unheard of in a UN organization, but for IARC, such unethical interventions seem to be par for the course. 

The US EPA staffers have been colluding with the IARC glyphosate panel members and vice versa. Lamar Smith, Chairman of the House Committee on Science, Space and Technology, wrote a letter on 25 October 2016 to the EPA’s Gina McCarthy on how the EPA was quietly involved in the IARC glyphosate monograph, removed their CARC report (on advice from the Environmental Defense Fund’s Christopher Portier) and provided untruthful and misleading statements to Congress regarding their involvement in IARC’s glyphosate monograph.

How to get IARC fit again?

IARC is not fit for purpose. Can it be saved or should it be shut down?

As it stands, IARC’s managers and scientists seem impervious to any criticism and believe they can continue to ignore the outrage they have instigated. Wild, Straif, and Guyton continue to attack (they don’t see the scandal they have caused); they will not go nor will they retract the glyphosate monograph.

The way to deal with this is easy. In a previous blog, I showed how IARC is only nominally a WHO agency (voted into existence during a WHO plenary more than 50 years ago). They are autonomous and dependent on the 25 member states who fund it. If those 25 states intervene or stop funding their political shenanigans, then IARC will be forced to become a responsible agency. With the Chaffetz and Smith letters, the US seems to be in the process of defunding IARC. If several other member states do the same, they will have to learn to play by the rules and adopt some scientific integrity.

It seems to be a no-brainer that the IARC head, Christopher Wild, must resign. He has not been able to control the behavior of his activist scientists and communications team, and their unethical actions have disgraced the agency and the reputation of the UN. The member states need to act or simply stop funding the agency. The WHO, in a perfect world, should try to put some moral weight on the agency to speed up the reforms, but for that to happen, something would need to happen to Margaret Chan!

Change the shape of IARC

Another option is to break up IARC and reform it with a more modern definition of risk assessments. A study by ten toxicologists has just been released that shows how IARC’s hazard assessment is outdated, outmoded and inadequate for cancer research and risk management. See press release. Dismantling IARC may be the important first step in rebuilding proper cancer research.

The ten toxicologists conclude that IARC has taken us down the wrong path:

The hazard and risk characterization approach avoids the unintended downsides of treating health scares, incurring unnecessary economic costs and the diversion of public funds, which could be spent more wisely, into unnecessary research.

IARC, as it stands today, is unnecessary. It lacks scientific integrity. It is acting in an unethical manner.

It is not fit for purpose.

This article appeared originally on Daviid Zaruks’ blog under the title “Is IARC Fit for Purpose?” and is being reproduced here with permission of the author.

David Zaruk is a Belgian-based environmental-health risk policy analyst specializing in the role of science in policy and societal issues. He blogs under the pseudonym: The Risk-Monger. Follow him on Twitter at @zaruk

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
skin microbiome x final

Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing

Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.